Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users

Ellen Smit, Richard David Semba, Erin Pilibosian, David Vlahov, Waimar Tun, Lisa Purvis, Alice M. Tang

Research output: Contribution to journalArticle

Abstract

We determined anthropometric measurements (including height, weight, circumferences, and skinfolds) and self-reported symptoms related to body habitus changes in 324 HIV-seropositive and HIV-seronegative inner city injection drug users (IDUs) who participated in a sub-study from the ALIVE (AIDS Linked to Intravenous Experiences) cohort. Participants who reported lipoatrophy in body parts had consistently lower anthropometric measurements and those reporting adiposity had correspondingly higher anthropometric measurements than participants who did not report these changes. Peripheral lipoatrophy was more common among all HIV-seropositive than HIV-seronegative participants, however, it was not associated with highly active antiretroviral therapy (HAART) (39% HIV-seronegatives; 58% HIV-seropositive not receiving HIV treatment [No Tx]; 49% HAART, p = 0.04). Central adiposity was more common among HAART (52%) than No Tx (26.6%) and HIV-seronegative (42%) participants (p = 0.001). However, waist circumference, while somewhat higher among HAART than No Tx participants, did not differ significantly from HIV-seronegative participants (85.2 cm HIV-seronegatives; 83.3 cm No Tx; 85.8 cm HAART). A large proportion of those who reported peripheral lipoatrophy also reported central lipoatrophy (76.9% HIV-seronegatives; 69.6% No Tx; 66.2% HAART). A large proportion of those who reported central adiposity also reported adiposity of the peripheral sites (88.1% HIV seronegatives; 66.7% No Tx; 74.3% HAART). The combination of lipoatrophy and adiposity was associated with HAART treatment (6% HIV-seronegatives; 3% No Tx; 16% HAART, p = 0.002), but may be driven by the association with adiposity. These data suggest validity of self-reports for body habitus changes among injection drug users.

Original languageEnglish (US)
Pages (from-to)19-30
Number of pages12
JournalAIDS Patient Care and STDs
Volume19
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Drug Users
Highly Active Antiretroviral Therapy
HIV
Injections
Adiposity
Waist Circumference
Human Body
Self Report
Acquired Immunodeficiency Syndrome

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Leadership and Management
  • Nursing(all)

Cite this

Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users. / Smit, Ellen; Semba, Richard David; Pilibosian, Erin; Vlahov, David; Tun, Waimar; Purvis, Lisa; Tang, Alice M.

In: AIDS Patient Care and STDs, Vol. 19, No. 1, 01.2005, p. 19-30.

Research output: Contribution to journalArticle

Smit, Ellen ; Semba, Richard David ; Pilibosian, Erin ; Vlahov, David ; Tun, Waimar ; Purvis, Lisa ; Tang, Alice M. / Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users. In: AIDS Patient Care and STDs. 2005 ; Vol. 19, No. 1. pp. 19-30.
@article{e3b182d4e274484abc7b13e45adc80f5,
title = "Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users",
abstract = "We determined anthropometric measurements (including height, weight, circumferences, and skinfolds) and self-reported symptoms related to body habitus changes in 324 HIV-seropositive and HIV-seronegative inner city injection drug users (IDUs) who participated in a sub-study from the ALIVE (AIDS Linked to Intravenous Experiences) cohort. Participants who reported lipoatrophy in body parts had consistently lower anthropometric measurements and those reporting adiposity had correspondingly higher anthropometric measurements than participants who did not report these changes. Peripheral lipoatrophy was more common among all HIV-seropositive than HIV-seronegative participants, however, it was not associated with highly active antiretroviral therapy (HAART) (39{\%} HIV-seronegatives; 58{\%} HIV-seropositive not receiving HIV treatment [No Tx]; 49{\%} HAART, p = 0.04). Central adiposity was more common among HAART (52{\%}) than No Tx (26.6{\%}) and HIV-seronegative (42{\%}) participants (p = 0.001). However, waist circumference, while somewhat higher among HAART than No Tx participants, did not differ significantly from HIV-seronegative participants (85.2 cm HIV-seronegatives; 83.3 cm No Tx; 85.8 cm HAART). A large proportion of those who reported peripheral lipoatrophy also reported central lipoatrophy (76.9{\%} HIV-seronegatives; 69.6{\%} No Tx; 66.2{\%} HAART). A large proportion of those who reported central adiposity also reported adiposity of the peripheral sites (88.1{\%} HIV seronegatives; 66.7{\%} No Tx; 74.3{\%} HAART). The combination of lipoatrophy and adiposity was associated with HAART treatment (6{\%} HIV-seronegatives; 3{\%} No Tx; 16{\%} HAART, p = 0.002), but may be driven by the association with adiposity. These data suggest validity of self-reports for body habitus changes among injection drug users.",
author = "Ellen Smit and Semba, {Richard David} and Erin Pilibosian and David Vlahov and Waimar Tun and Lisa Purvis and Tang, {Alice M.}",
year = "2005",
month = "1",
doi = "10.1089/apc.2005.19.19",
language = "English (US)",
volume = "19",
pages = "19--30",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users

AU - Smit, Ellen

AU - Semba, Richard David

AU - Pilibosian, Erin

AU - Vlahov, David

AU - Tun, Waimar

AU - Purvis, Lisa

AU - Tang, Alice M.

PY - 2005/1

Y1 - 2005/1

N2 - We determined anthropometric measurements (including height, weight, circumferences, and skinfolds) and self-reported symptoms related to body habitus changes in 324 HIV-seropositive and HIV-seronegative inner city injection drug users (IDUs) who participated in a sub-study from the ALIVE (AIDS Linked to Intravenous Experiences) cohort. Participants who reported lipoatrophy in body parts had consistently lower anthropometric measurements and those reporting adiposity had correspondingly higher anthropometric measurements than participants who did not report these changes. Peripheral lipoatrophy was more common among all HIV-seropositive than HIV-seronegative participants, however, it was not associated with highly active antiretroviral therapy (HAART) (39% HIV-seronegatives; 58% HIV-seropositive not receiving HIV treatment [No Tx]; 49% HAART, p = 0.04). Central adiposity was more common among HAART (52%) than No Tx (26.6%) and HIV-seronegative (42%) participants (p = 0.001). However, waist circumference, while somewhat higher among HAART than No Tx participants, did not differ significantly from HIV-seronegative participants (85.2 cm HIV-seronegatives; 83.3 cm No Tx; 85.8 cm HAART). A large proportion of those who reported peripheral lipoatrophy also reported central lipoatrophy (76.9% HIV-seronegatives; 69.6% No Tx; 66.2% HAART). A large proportion of those who reported central adiposity also reported adiposity of the peripheral sites (88.1% HIV seronegatives; 66.7% No Tx; 74.3% HAART). The combination of lipoatrophy and adiposity was associated with HAART treatment (6% HIV-seronegatives; 3% No Tx; 16% HAART, p = 0.002), but may be driven by the association with adiposity. These data suggest validity of self-reports for body habitus changes among injection drug users.

AB - We determined anthropometric measurements (including height, weight, circumferences, and skinfolds) and self-reported symptoms related to body habitus changes in 324 HIV-seropositive and HIV-seronegative inner city injection drug users (IDUs) who participated in a sub-study from the ALIVE (AIDS Linked to Intravenous Experiences) cohort. Participants who reported lipoatrophy in body parts had consistently lower anthropometric measurements and those reporting adiposity had correspondingly higher anthropometric measurements than participants who did not report these changes. Peripheral lipoatrophy was more common among all HIV-seropositive than HIV-seronegative participants, however, it was not associated with highly active antiretroviral therapy (HAART) (39% HIV-seronegatives; 58% HIV-seropositive not receiving HIV treatment [No Tx]; 49% HAART, p = 0.04). Central adiposity was more common among HAART (52%) than No Tx (26.6%) and HIV-seronegative (42%) participants (p = 0.001). However, waist circumference, while somewhat higher among HAART than No Tx participants, did not differ significantly from HIV-seronegative participants (85.2 cm HIV-seronegatives; 83.3 cm No Tx; 85.8 cm HAART). A large proportion of those who reported peripheral lipoatrophy also reported central lipoatrophy (76.9% HIV-seronegatives; 69.6% No Tx; 66.2% HAART). A large proportion of those who reported central adiposity also reported adiposity of the peripheral sites (88.1% HIV seronegatives; 66.7% No Tx; 74.3% HAART). The combination of lipoatrophy and adiposity was associated with HAART treatment (6% HIV-seronegatives; 3% No Tx; 16% HAART, p = 0.002), but may be driven by the association with adiposity. These data suggest validity of self-reports for body habitus changes among injection drug users.

UR - http://www.scopus.com/inward/record.url?scp=12844273418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12844273418&partnerID=8YFLogxK

U2 - 10.1089/apc.2005.19.19

DO - 10.1089/apc.2005.19.19

M3 - Article

VL - 19

SP - 19

EP - 30

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 1

ER -